ISSUE NO.3 www.ipriasia.com
Medical Technology - Equipment & Device - Pharmaceutical - Manufacturing - Health Care & Technology Information
Innovating During the COVID-19 Pandemic More than 20 new cases of Indian COVID-19 variant found in Japan Who are the top medical device manufacturers in Japan in 2020? DIGITAL ISSUE NO.03 : MAY 2021
1
2
ASIA PHARMED & HEALTHCARE THAILAND
Editor’s note ADDRESS IPRI Co.,Ltd. 58/2 Soi Phrom Sri, Sukhumvit Rd., Khlong Tun Nuea, Wattana, Bangkok 10110 Thailand Tel: +66 (0) 2392 2011 Fax: +66 (0) 2392 2012 Website: www.ipriasia.com MANAGEMENT Publisher Wannee Sananwatananont : wannee@ipriasia.com MEDIA DIRECTOR Laverne S. Taypin : lawant@ipriasia.com ADMINISTRATION / DIGITAL SUBSCRIPTION Rawiphan Promgam : rawiphan@ipriasia.com DIGTAL TEAM / PRODUCTION Wiratchada Sukkhathon : pure@ipriasia.com Watcharida Sukkhathon : preem@ipriasia.com
As the world faces challenges due to Covid-19, which has disrupted lifestyles of people regardless of their race or skin color, all across the world. And as the digital technologies, the upcoming 5G network have provided people with fast and broad access to information, helping to connect people across borders. Increasing production efficiency in the manufacturing sectors, thanks to the full speed and unlimited connectivity, making the world a smaller place like one could never have imagined before. This edition of Digital Magazine for industrial sector of Pharmaceutical, Medical Equipment & HealthCare that you are now reading the latest updates on modern technologies for the manufacturing industry of Pharmaceutical, Medical Equipment & HealthCare so that everyone can access latest technologies from the manufacturers and for the manufacturing industry instantly and with efficiency. It also allows you to access to information in digital format enable you can easily forward and share the information to those that are relevant. I hope that our readers will benefit from Asia PharMed & HealthCare Thailand Digital issue. As for any of the latest developments on new technologies that you would like to share, kindly send to us at editor@ipriasia.com. We are more than happy to be the medium for sharing your news.
Lavene S.Taypin
DIGITAL ISSUE NO.03 : MAY 2021
3
CONTENTS Thailand news
6 Coronavirus disease 2019 (Covid 19) 8 12 14 15
Pharmaceutical
PharmaLinea flags market opportunity with the 1st supplement clinically proven to save iron-deficient children from anemia
18 20 22 4
Innovating During the COVID-19 Pandemic
Special Article
10
How Sandvik Coromant helped “Monster” Mike to create a truly life-changing innovation
Healthcare & Technology Temasek-Backed Halodoc Raises $80M Series C To Enhance Its Digital Healthcare Platform Accolade Acquires PlushCare For Up To $450M To Offer A Digital Primary Care Platform
Thailand lab post webinars
16
Covid -19 Update
How to Adapt your Business during the COVID-19 Crisis for Laboratory Industry
MEDICAL TECHNOLOGY
Surface Engineering in Medical Technology From DLC to Plasma and Beyond
MEDICAL & Device NEWS Who are the top medical device manufacturers in Japan in 2020? Complex Drug Development and Manufacturing-Steroids, Peptides, and Hormones ASIA PHARMED & HEALTHCARE THAILAND
24
Medical Technology Association of Japan The environment surrounding the medical device industry has been changing drastically.
INDUSTRY ASSOCIATION
26 Morals and the Covid-19 Vaccine 28 Market Opportunities in Thailand for the Medical and HealthCare 30 Italian Value Chain 31 Hope for humanity
More than 20 new cases of Indian Covid-19 variant found in Japan
DIGITAL ISSUE NO.03 : MAY 2021
5
Thailand news
By world health organization country office for thailand
SPOTLIGHT • Today, 2,041 new cases of laboratory-confirmed COVID19 were announced by the Ministry of Public Health of Thailand. 31 new deaths were reported today. In addition, 981 patients are considered to have serious illness, of which 278 are currently receiving ventilatory support. • Of the cases reported in Thailand to date, 57.7% (40,984) have recovered, 0.4% (276) have died, and 41.9% (29,765) are receiving treatment or are in isolation: (21,473 are in conventional hospitals and 8,292 in field hospitals). • The 2,041 laboratory-confirmed cases reported today include 1,943 cases detected through the routine surveillance system: (testing of people presenting at a healthcare facility for a variety of reasons, including presence of COVID-19 symptoms, contact with a case, concern about a possible exposure). 97 cases identified through active case finding: (testing of people in the community at the initiative of public health authorities). 1 case detected in quarantine after arriving in Thailand from another country. • Between 1 April 2021 and 3 May 2021, 42,162 confirmed cases have been reported, of which 35,584 were detected through the routine surveillance system, 6,349 through active case finding, and 229 are individuals who entered Thailand from other countries. 182 cases have died. • The 10 Provinces reporting the greatest number of laboratory-confirmed COVID-19 cases today are Bangkok (675), Nonthaburi (277), Samut Prakan (161), Chonburi (153), Surat Thani (69), Chiang Mai (55), Pathum Thani
6
ASIA PHARMED & HEALTHCARE THAILAND
(51), Samut Sakhon (45), Songkhla (27), and Nakhon Pathom (23). • The 5 provinces reporting the greatest number of laboratory-confirmed COVID-19 cases in the current wave (1 April-3 May) are Bangkok (13,958), Chiang Mai (3,673), Chonburi (2,762), Samut Prakan (2,167), and Nonthaburi (2,141). UPDATE FROM THE CCSA • The Khlong Toei cluster The discovery of COVID-19 cases in Khlong Toei has raised concern about spread of infection due to crowded communities and slum conditions. Active case finding in these communities has identified 99 cases from a total of 1,336 samples collected. More testing will be conducted across the district in the next eight days. • Advice for the General Public Families should ensure that anyone who has to leave home for any reason avoids subsequent interaction with elderly family members to prevent COVID-19 transmission. The Department of Disease Control in the Ministry of Public Health advises those living in the same house-hold to frequently santinize all shared spaces and items, including dining tables, door knobs, utensils and remote controls. Individuals should also always wear a mask, especially in the company of an elderly person. WHO guidance was cited, stressing that looking after one’s mental health is as important as looking after one’s physical health. • Preventive measures Authorities have tightened controls along Thailand’s border with Malaysia and Cambodia. Local communities are urged to fully cooperate.
If you are caring for yourself or a loved one at home, how can you keep everyone safe from COVID-19 ? Who should be cared for at home? How to prevent COVID-19 infection to other family members? What red flags should you look for that tell you it is time to contact the health care provider? WHO’s Dr April Baller explains in Science in 5
SITUATION ANALYSIS The fluctuation in COVID-19 case numbers being reported in recent days (sometimes lower, sometimes higher) means that it’s not currently possible to judge the direction in which the overall situation is moving. It will also take 1-2 weeks before it will be possible to reliably assess the degree to which recently imposed (stronger) public health and social measures will impact on transmission rates. The daily increase in the number of COVID-19 cases with serious illness, including those requiring ventilatory support is a serious cause for concern and is directly related to the recent upsurge in new cases. Based on the experience in Thailand and in other countries, we know that a small proportion of all COVID19 cases will develop serious illness, and studies have shown that a significant number of people who require ventilation will not recover despite receiving the best possible care that medical science can provide. Until the current outbreak is contained, this situation will unfortunately continue An analysis of 52 fatalities in Bangkok by the Department of Disease Control reported today indicated that the majority of these people had close contact with a confirmed case in the household. In addition, it is evident that most fatalities have identifiable risk factors, including old age, obesity and medical conditions such as diabetes and heart disease. Every one of these cases could have been prevented by following basic measures for infection prevention and control. If we interrupt chains of transmission, we can stop COVID-19 in it’s tracks, relieve the burden on healthcare facilities, protect healthcare workers and save lives.
EXPLAINER: Lowering COVID-19 risks for yourself and for others If COVID-19 may be spreading in your community, stay safe by taking simple precautions such as physical distancing, wearing a mask, avoiding crowds, cleaning your hands with soap and water or alcohol-based hand rub, and coughing into a bent elbow or tissues and disposing of them safely Poorly-ventilated indoor places are hotspots for COVID transmission, so whenever possible, ensure that your home is always well-ventilated by opening windows and doors. While going outside may be the only way to help some individuals cope with quarantine fatigue, staying within the safety of your own home is better. Outdoor dining, shopping or any form of social gathering raises the risk of infection as the chance of meeting people who have not been practising public health and social measures is much higher. Know your risk, control your risk: lower your risk! For young people living with or sharing the same compounds with the elderly and the vulnerable, it’s extremely important to take extra precautions in case you are infected, but not displaying symptoms Source : https://www.who.int/thailand/
DIGITAL ISSUE NO.03 : MAY 2021
7
COVID-19 Update
By Pharmaceutics International, Inc
Innovating During the COVID-19 Pandemic We Are Grateful for the Continued Efforts and Dedication of Our Employees to Ensure Uninterrupted Supply of Medicines to Our Customers and Patients. Pharmaceutics International, Inc., (Pii) is a premier CDMO, offering unparalleled scientific insight and depth of product knowledge, while supplying high-quality dosage forms that enhance the lives of patients worldwide. Pii provides customized and flexible solutions across several dosage forms and has experience with a broad range of compounds. For 25 years, Pii has been supporting its pharmaceutical partners (from virtual to multinational) with extensive technical capabilities, knowhow, and the highest level of customer service. With more than 400 development programs completed, Pii’s scientific team has extensive experience working with drug substances representing a range of physicochemical characteristics (and challenges). Pii’s specialized capabilities, multiproduct facilities, and in-depth knowledge allow them to work with potent compounds and hormones, develop complex dosage forms, and support varied manufacturing processes. Continuous investment and innovation are core elements of Pii’s strategy, helping to ensure the company remains
8
ASIA PHARMED & HEALTHCARE THAILAND
maximally relevant to prospective biopharmaceutical partners by delivering on all commitments. In addition to recruiting the industry’s best talent, Pii seeks avenues for further innovation, continues to build cuttingedge technology assets, and reinforces its existing pharmaceutics know-how to empower scientific advancement, to share knowledge, and to pursue excellence across the entire organization. Pii continually monitors evolving industry trends and technical innovations to stay ahead of forthcoming challenges and proactively develop solutions and services to overcome potential issues. One major driver of change is the ongoing evolution toward increasingly personalized medicine, which in some instances translates into lower production demands or higher-value products. Processing costly drug substances — which often require further enhancements of containment procedures — increases the requirements for innovation in drug development and formulation. Pii is always investing in people and capabilities. One recent example is an expansion of sterile capabilities, including lyophilization and a new fully robotic filling line for small batch processing, in response to increased demand for sterile product processing.
Formulation expertise will become increasingly critical as new modalities enter commercialization and drug products become even more complex. Pii continues to track industry developments regarding biologics, microbiome therapeutics, and cell and gene therapy, expanding their expertise and capabilities where they can determine the best synergies. In addition to the flexibility that Pii’s facilities offer customers, such as dedicated production suites, they have been able to adapt standard processing practices to accommodate some very unique programs. The company has a long history of problem-solving and, through close collaboration with customers, continues to innovate to progress product development. Pii is currently in discussion with several existing and prospective customers to support product development initiatives related to COVID-19, including antiviral therapeutics and vaccines. Thus far, the COVID-19 crisis has not impacted Pii’s regular operations, as we have become adept at working in an increasingly “self-monitored” environment. We are grateful for the continued efforts and dedication of our employees to ensure uninterrupted supply of medicines to our customers and patients. From the beginning, Pii has been declared an essential business by our local government, allowing us to sustain full operation and employment for our teams. Our employees have worked diligently to assure continuity of supply and to keep all R&D projects on track. Employee safety remains our number one priority. To help ensure the safety of our employees and partners and to protect supply to patients, we have taken extensive actions — in line with guidelines issued by the U.S. CDC, the WHO, and local authorities where we operate — including re-emphasizing good hygiene practices, severely r estricting visitor access to our sites, reorganizing our workflows to maximize social distancing, limiting employees to business-critical travel (where permitted by local government policy), facilitating safer commuting alternatives, and employing remote-working strategies. We continue to survey deep into our supply chain and have not identified any significant risk, delay, or concern that may have a substantial effect on delivery of any product or clinical trial supplies.
delays are mitigated. We wish to express our thanks to all our customers and partners for your trust, collaboration, and support. Pharmaceutics International, Inc., (Pii) is a premier CDMO, offering unparalleled scientific insight and depth of product knowledge, while supplying high-quality dosage forms that enhance the lives of patients worldwide. Pii provides customized and flexible solutions across several dosage forms and has experience with a broad range of compounds. For 25 years, Pii has been supporting its pharmaceutical partners (from virtual to multinational) with extensive technical capabilities, knowhow, and the highest level of customer service. With more than 400 development programs completed, Pii’s scientific team has extensive experience working with drug substances representing a range of physicochemical characteristics (and challenges). Pii’s specialized capabilities, multiproduct facilities, and in-depth knowledge allow them to work with potent compounds and hormones, develop complex dosage forms, and support varied manufacturing processes. At Pharmaceutics International, Inc. (Pii), our motto is “challenges frame opportunities.” We are a contract development and manufacturing organization (CDMO) with a passion for problem-solving. Emphasizing collaboration, our experts complete projects on time with the highest quality standards, all from our Hunt Valley, Maryland campus. Pii’s campus includes four cGMP and FDA inspected facilities, 70 manufacturing suites with all the necessary analytical testing capabilities on site, and four integrated aseptic filling suites delivering quality, safety, and efficiency. Experienced with small and large molecule compounds, we have special expertise in developing and manufacturing complex parenteral products, extended release formulations, and non-aqueous injectable drug products. We can also overcome stability challenges with precision lyophilization cycle development and production. Pii’s Pharmaceuticals Know-How™ can quickly and safely advance your drug from discovery through clinical testing to commercialization. Find out more at www.pharm-int.com
Our operations, procurement, business development, and project management professionals are dedicated to maintaining business as usual and ensuring any potential
DIGITAL ISSUE NO.03 : MAY 2021
9
Special article Article by sandvik Coromant
Heart and leg of a champion
How Sandvik Coromant helped “Monster” Mike to create a truly life-changing innovation “Monster” Mike Schultz, a snowmobile racer since his high school days, went pro in 2003, and within five years was one of the top five snocross racers in the world. But an accident one winter day in 2008 changed everything. “I had a bad start during the qualifying race and was pushing hard to catch up so I could make the finals,” says Schultz. “Coming down a hill, though, I got bucked off the sled and landed wrong. My knee basically blew apart.” Things quickly went from bad to worse. A nearby snowstorm grounded all helicopter flights that day, so Schultz had to ride by ambulance to the nearest trauma centre. “It was five hours before I got to a trauma surgeon,” he says. “They tried to save it, but three days after the accident I’d gone through 47 units of blood and my kidneys were shutting down. The doctors woke me up to tell me they were amputating my leg.” Schultz spent 13 days in hospital. “I rebounded pretty quickly because of my physical condition,” he says. “They sent me home on Christmas Day. Five weeks later I had my first prosthetic leg. To be able to walk again was an amazing feeling.” Despite this, Schultz thought his racing days were over. “I didn’t want to race if I couldn’t compete at the level I did before. I kind of wrote it off.” Passion, determination and a large dose of entrepreneurial spirit have allowed Mike Schultz to thrive in his career despite the loss of a limb. Life presents each of us with challenges from time to time, but For more information rarely is the challenge the loss of a limb. In an instant, the ability to climb a staircase or tie a shoe – things that most people take for granted – can suddenly become far more difficult. This was the case with Mike Schultz, but he refused to let that event prevent him from making the most of his life.
10
ASIA PHARMED & HEALTHCARE THAILAND
But several months later, he heard about the X Games Supercross Adaptive sports competition and knew then that he had to give it a try. The problem was finding a suitable prosthetic, one that would not only help him compete, but actually win. In order to do so you need a great design and the best quality tooling to ensure a precision fit. With an indefatigable spirit, help from friends in the racing community and Sandvik Coromant Mike Schultz soon designed and built one ideal for extreme sports.
“Sandvik Coromant supported in the machining process, the materials that are used in the medical field for prosthetics for joints and screws needs to stand up totough conditions. Sandvik Coromant has developed machining techniques and tooling to stand up to those materials. With Mikes hands and Sandvik Coromant tools hecan create groundbreaking innovations, truly life-changing innovations”, says Tiffany Long, Sales Engineer at Sandvik Coromant. Sandvik Coromant is at the forefront of manufacturing tools, machining solutions and knowledge that drive industry standards and innovations. Since the start in 1942 Sandvik Coromant have been driven by a determination to solving problems and are currently represented in more than 150 countries with over 7,600 staff. The research and development team comprises more than 500 people working at several research and testing facilities around the world. The patent portfolio holds more than 520 patent families, and each year adding 30 to 40 new patents. And also adding some 2,500 new products to the market every year as well as new machining methods and machining concepts that reflect the demands and challenges of new materials and the industry.
Over the past eleven years, Monster Mike has made a name for himself in the world of adaptive sports, taking home ten gold medals in the Motocross, Snocross, and Snow Bike categories at the X Games competition, as well as gold and silver at the 2018 Winter Paralympics. Schultz’s name spread even further from his appearance on the American Edge Factor show about modern manufacturing and innovation, which was sponsored at the time by Sandvik Coromant. Sandvik Coromant offers a large of advanced tooling and machining solutions for medical devices: hip joints, bone screws, pedicle screws, dental implants and bone plates “One of the best ways to share and gain knowledge is to collaborate with others. Sandvik Coromant is the global leader in metal-cutting technology and innovation, it’s part of our responsibility to help our customers be successful in their endeavors as well as to help people outside the industry to understand the value of metal cutting in modern life, By working together we drive continuous improvement and progress and at the same time meet the manufacturing challenges of today and the future.” says Senior Project Leader JoAnn Mitchell, Sandvik Coromant USA, about the sponsorship.
Mike Schultz has not looked back since Less than five months after the accident, Schultz and his new knee raced motocross at Michigan’s Extremity Games, qualifying him for the 2009 ESPN Summer X Games Supercross. “Participating in an event like that was a real eye-opener,” says Schultz. “It opened me up to relationships with other amputees, where I could learn stuff from them, and them from me. From that point on, it’s been a whole new world.”
Apart from his passion for all things fast, Schultz has developed another love, this one a gift to athletes like himself. His work on high-performance prosthetics has led him to open his own manufacturing company, BioDapt, which now markets his high-impact, highly adjustable Moto Knee and the VF2 prosthetic sports foot.
DIGITAL ISSUE NO.03 : MAY 2021
11
Pharmaceutical Article by PharmaLinea
PharmaLinea flags market opportunity with the 1st supplement clinically proven to save iron-deficient children from anemia What’s the news: >Your< Iron Syrup, a private label children’s iron supplement by PharmaLinea, has recently been clinically proven to increase ferritin levels in irondeficient children by 69%, thus enabling them to avoid anemia. The study, published in MDPI Nutrients, is the first to show anemia in iron-deficient children can be avoided through supplementation. Why is it important: Iron supplements are proven to be able to create high market growth and with clinical proof the opportunity is even bigger. Iron deficiency has an especially high incidence in Southeast Asia. Who should read this: Pharmaceutical and food supplement brands, looking to expand their portfolio. PharmaLinea has a rich history of success with their private label iron supplements, but now they have taken a step further by publishing a clinical trial on their liquid iron product for children. Matevž Ambrožič, Marketing & PR Director at PharmaLinea, explains: “Products from >Your< Iron Line have been successfully launched by companies such as subsidiaries of STADA and Teva in over 21 markets. However, the market opportunity is not very obvious to everyone, because iron supplements can be a relatively small and undeveloped market in certain countries and looking at market reports won’t
12
ASIA PHARMED & HEALTHCARE THAILAND
help you notice it. Iron drugs usually dominate the market but we have seen many cases now where our products, or even competitors, are launched into the market and create market growth. For example, a partner of ours in Europe launched >Your< Iron Line and is now reaching 500.000 ordered units a year, in a market of under 20 million people. What is required is 3 key advantages: great taste, absence of side effects, and high efficacy. We wanted objective proof of the latter, hence the investment into a clinical trial.” The trial PharmaLinea performed on >Your< Iron Syrup was a randomized, double-blind, placebo-controlled intervention. It sets a high quality standard, as it was carried out in 15 research centers and on a statistically significant number of non-anemic children (85). “No other trial on children’s iron deficiency is directly comparable. They are either performed on anemic subjects and/or with an iron dose that categorizes the product as a drug and not a supplement,” Ambrožič claims. He goes on to say that pharmaceutical companies and their strict demands regarding scientific proof were the main reason for the clinical trial. “Our most successful clients promote our iron products through medical detailing and have high standards on the science behind products. We wanted this study to be a powerful tool to help their marketing and convince doctors. Around 15%
of pre-school children are iron-deficient and not yet anemic and therefore can’t be prescribed with drugs. So far doctors have had no clinically proven supplements that they could recommend to them. They could only hope that the children’s iron levels will not drop to anemic. Our clinical study in now the first to prove anemia in children can be avoided by taking an iron supplement. This is why we think the study will be such an important differentiation factor to separate our iron products from the competition. Thankfully, results turned out to be exceptional, so the investment was worth it.”
>Your< Iron Syrup group also showed significantly higher hemoglobin (p= 0,02), hematocrit (p= 0,02), and erythrocyte levels (p= 0,03). Several widely recognized biological indicators of iron status were thus significantly improved. Compliance was 92% and there was no significant difference between the experiment arms. The latter is true for the frequency of side effects as well. Only one severe adverse event (abdominal pain) in 85 children in 12 weeks was evaluated as possibly linked to supplementation. The product was thus found to be very well tolerated and safe.
The results of the trial can be summarized as follows: Children that took >Your< Iron Syrup were able to increase their ferritin by 69% (14,5μg/l -> 24,5μg/l) – to levels significantly above the threshold at risk of anemia (20μg/l). The placebo group retained at-risk levels despite receiving dietary advice.
For More Information : https://pharmalinea.com/news/published-your-iron-syrup-clinical-trial
DIGITAL ISSUE NO.03 : MAY 2021
13
Healthcare & Technology By cb insights
Temasek-Backed Halodoc Raises $80M Series C To Enhance Its Digital Healthcare Platform Halodoc expects a steep rise in the demand for services like online medical consultations in a pandemic-stricken market. Here are the top-line bullets you need to know. Halodoc, which offers online medical consultations and medicine delivery services, has raised an $80M Series C. The round was led by Astra Digital Internasional with participation from Temasek, Telkomsel Mitra Inovasi, and Novo Holdings, among others. HOW’S THE COMPANY PERFORMING? Indonesia-based Halodoc is a digital health platform that provides online consultations with doctors and an app that delivers medicines and supplements from over 4,000 pharmacies. Its primary business lines are drug delivery services, virtual consultations, and patient appointment bookings.
Halodoc recently launched an online appointment service for residents to help them book Covid-19 tests and vaccinations as well as a drive-through Covid-19 testing service. The Indonesian Ministry of Health appointed the startup to help administer the national vaccination program, and Halodoc has helped vaccinate more than 50,000 citizens within the first month of the rollout. For More Information : https://www.cbinsights.com/research/halodoc-series-c-funding/
The company reportedly caters to 20M monthly active users and has over 20,000 registered doctors.
Source : Halodoc 14
ASIA PHARMED & HEALTHCARE THAILAND
Source: PlushCare
Accolade Acquires PlushCare For Up To $450M To Offer A Digital Primary Care Platform The acquisition follows Accolade’s recent $460M telemedicine deal to enhance its service portfolio. Here are the top-line bullets you need to know. Health benefits provider Accolade has acquired Plush Care, a digital primary healthcare platform, in a $450M cash-and-stock deal. Up to $70M is payable upon hitting revenue targets. WHO ARE THE PARTIES TO THE DEAL? PlushCare: California-based PlushCare is a virtual primary care platform that digitally connects patients to doctors and mental health experts. The platform allows physicians to provide online diagnoses and treatment consultations to their patients. The company has a headcount of about 150 employees and has served over 400,000 patients to date. PlushCare reported an unaudited revenue of approximately $35M in 2020.
Accolade: Accolade, based in Seattle and Philadelphia, offers a health benefits platform to employers and members that provides a suite of services. In July 2020, the company raised $220M from an IPO at a valuation of $1.2B. Presently, the company serves 9M members and 400 customers. Its employee headcount is approximately 2,000. It recently acquired telemedicine company 2nd.MD in January for $460M. For More Information : https://www.cbinsights.com/research/accolade-acquires-plushcare/
DIGITAL ISSUE NO.03 : MAY 2021
15
Thailand lab post webinars By Thailand LAB
Thailand LAB INTERNATIONAL & Bio Asia Pacific are proud to present a webinar series on the topic
“
How to Adapt your Business during the COVID-19 Crisis for Laboratory Industry
“How to Adapt your Business during the COVID-19 Crisis for Laboratory Industry” Bangkok, Thailand – April 12, 2021 – VNU Asia Pacific, the organizer of Thailand LAB INTERNATIONAL, is ready to kick off the roadmap for 2021 show promotion and confirm the organization of Thailand LAB INTERNATIONAL, Southeast Asia’s leading exhibition and conference on Analytical Laboratory Technologies, Life Sciences, and Biotechnology Innovations (the 11th edition). The trade show will take place
16
ASIA PHARMED & HEALTHCARE THAILAND
during September 1–3, 2021 at BITEC, Bangkok together with Bio Asia Pacific, the new leading conference and exhibition platform for Biotechnology, Life Sciences and Smart Health in Asia Pacific. VNU Asia Pacific, together with Science and Technology Trade Association (STTA), Thailand Center of Excellence for Life Sciences (TCELS) and more related partners from both government and private sectors, are collaborating to develop the trade show to serve the laboratory industry for the Southeast-Asia region.
Turn Crisis into Opportunity for Success Even during the challenges generated by the COVID-19 pandemic last year, Thailand LAB INTERNATIONAL still continued with the impressive success we expected. Thailand LAB INTERNATIONAL, along with Bio Asia Pacific 2020, concluded with 109 exhibiting companies and 8,067 trade visitors. 65% of total trade visitors were physical visitors while 35% were virtual. We had 47 physical conferences and 47 purely virtual conferences, plus 38 hybrid conferences (physical with live streamed content at YouTube LIVE). We had 328 successful virtual meetings over the course of three days. The main attraction of the exhibition hall, called “Bio Square,” featured the grandiose Opening Ceremony of the shows, including networking functions, start-up pitching, panel discussions, and thoughtful leadership. Following its success last year, ‘Bio Square’ will once again appear as the show’s highlight, with a further developed format to increase interest. In 2021, the show will focus more on the international attendee and also target local people who are interested in attending our show in-person or via virtual / online platforms, whether the travel restrictions remain or not, meeting the organizer’s mission to create an interaction platform for trading, knowledge sharing, research and increased business opportunities for the industry. “From last year, we have learned to adjust ourselves to the “New Normal” that we are in by promoting the usage of virtual exhibition platforms, online business matching systems, instant video calls, live streaming, and live broadcasting to respond to the changing needs of our customers. We have decided to focus more on local participants this year, and it was still a success because even though the number was relatively lower, the exhibitors were very satisfied with the quality of trade visitors,” stated Mr. Anucha Parnpichate, Project Manager of Thailand LAB INTERNATIONAL. “However, we are also monitoring the COVID-19 pandemic situation and have prepared a response plan and are prepared for every situation that may arise in the future. Our goal is to try to stimulate the market, increase the opportunities for business match-making and maintain the investment stages for the laboratory market. In 2021, the show will present more on the new technology, innovation, MedTech, Bio Tech, Med Tech and Digital Health.
Thailand LAB INTERNATIONAL & Bio Asia Pacific will open for registration from 1 May 2021 onwards.” Insight market information on the webinar series Due to the COVID-19 outbreak, the common routines of people around the globe have been impacted, as well as global economic stability. The virus continues to evolve and disrupt. The best solution to the pandemic is to understand the cause of the disease, the spread of infection and how it can be prevented, as well as keep up to date with the progress of the COVID-19 vaccine rollout in your country. This upcoming September, the organizer proudly presents the laboratory webinar series which also covers topics such as as surgical mask testing or controversial areas like cannabis in lab testing and more. The first webinar will start on May 20, 2021 and is on the topic “Surgical Mask Testing” by Assoc. Prof. Dr. Panich Intra, Rajamangala University of Technology Lanna, Thailand. The content will be divided into three parts including Quality of Face Mask: Testing, Regulation and Standard, Insight Interview with our keynote speaker for the journey of the mask testing institute, and end with a LAB Visit at the Research Unit of Electrostatic Applications in Energy and Environment. The webinar will be conducted in Thai only. If you are interested in attending, please register at https://forms.gle/YRxRQXmoWYYgggun7 Save the date: Thailand LAB INTERNATIONAL & Bio Asia Pacific showcases during September 1–3, 2021 at BITEC, Bangkok. For more information, please visit our websites: www.thailandlab.com or www.bioasiapacific.com
DIGITAL ISSUE NO.03 : MAY 2021
17
MEDICAL TECHNOLOGY Article BY Freudenberg Medical
Surface Engineering in Medical Technology From DLC to Plasma and Beyond New materials and technological advances continue to proliferate the medtech industry at a rapid rate and suppliers strive to offer innovative solutions to meet the demands of increasingly complex components and devices. A wide range of specialized materials are used today and many of those materials are suitable for the intended finished use only after the application of a customized surface treatment. These treatments can result in reduced friction, improvement of haptic properties, the introduction of chemical functionalities, and improved medium resistance of the materials. To meet this growing demand, Freudenberg Medical utilizes traditional coating methods like wet chemicals and state-of-the-art methods such as plasma treatments in order to alter the surface properties of medical components.
18
ASIA PHARMED & HEALTHCARE THAILAND
Surface modifications allow a variety of unique customer needs to be addressed. For example, color coating is a surface modification which enables control of the base materials’ transparency and optical properties. A plasma treatment is another option which will reduce friction; silicone itself has a high friction coefficient and a plasma treatment will modify its friction properties. This can improve silicones manufacturability (particularly in automated assembly lines) and its ability to be used in low friction applications where gliding is necessary – such as with endoscopic catheters and the internal coating of flexible tubes used in cardiac pacemakers.
Surface modifications such as plasma coating directly influence the surfaceenergy of a component; this allows control and adjustment of the hydrophilic properties. Plasma processes enable multiple functionalities to be implemented within a single process; for example plasma enables a bioactive layer with good adhesion to be applied to a substrate in a single step. The surfaces are plasma coated, activated, or plasma etched using evironmentallyfriendly processes. A variety of component geometries can be altered with vacuum or tmospheric pressurized plasma, without solvent emissions or a time-consuming drying process. Small parts can be handled in bulk goods processes under a vacuum, while atmospheric pressure plasmas are well-suited for integration into existing process chains. Different systems for handling and coating are utilized depending on the specific geometry requirements of the component.
The basic type is Parylene N (polypara-xylene), which is characterized by a good gap penetration capability and a low friction coefficient. Parylene C has high chemical resistance and provides an excellent barrier effect against gases and moisture. Parylene D has long been used as a high-temperature Parylene due to its continuous use at a temperature of 100º C. A new, fluorinated Parylene, Parylene HT®, is used at even higher temperatures (up to 350º C) and has the highest gap penetration capability, a high UV resistance, and the lowest friction coefficient.
Another newer surface coating technology is diamond like carbon or DLC, which is biocompatible, amorphous, and can be produced by plasma-supported processes. It has a very low friction coefficient, good wear resistance, and a high layer of hardness resulting in a significantly higher stability for long-term implantable devices. By incorporating different chemical elements, DLC can be further adapted to special requirements. One example is an antibacterial effect which can be achieved via the infusion of metal particles such as silver
For More Informatiom :
Dr. Mark Ostwald, Vice President and General Manager of Freudenberg Medical – Carpinteria notes, “In many cases, our customers require specific material properties for their device and due to regulatory aspects we cannot modify the material chemistry. In these situations a customized surface treatment allows us to provide customers with individualized solutions.” The medtech field continues to expand to meet the demands of new treatments and the complexity of devices that are part of those solutions. Unfortunately, there are no universal answers, it is important to find a production partner with the experience and technical capabilities to provide the right solution for these specialized needs. Surface engineering is one of the many areas in which Freudenberg Medical is maximizing the flexibility of its processes and services to achieve continuous innovations that keep pace with the ever growing challenges of the healthcare industry.
https://www.freudenbergmedical.com/en/
Parylene coatings are another medically approved surface coating. These coatings are hydrophobic, inert, transparent, nonporous, biocompatible, biostable, and have an outstanding barrier effect against moisture, chemicals, and gases. These coatings also have a high dielectric barrier effect. Four different types of Parylene are produced.
DIGITAL ISSUE NO.03 : MAY 2021
19
MEDICAL & Device NEWS By Proclinical
Who are the top medical device manufacturers in Japan in 2020?
Japan stands as one of the world’s top contributors to the medical devices market. medical devices market in Japan is predicted to grow by JP¥695 billion (US$6.65 billion) between 2020-2024. This innovative industry continues to expand against the background of an ageing population and the unmet needs for minimally invasive treatment. We have ranked the leading medical device companies in Japan by 2019 revenue, looking at their medical devices segment results only. The list below shows the top 10 leading Japanese medical device companies in 2020:
10. Shimadzu Corporation Shimadzu Corporation is a Japanese company that specialises in manufacturing precision instruments, measuring instruments and medical equipment such as X-ray TV systems and angiography systems. With increased sales of diagnostic X-ray systems in Japan, the medical systems segment rose by 1.6% on a year-on-year basis.
20
ASIA PHARMED & HEALTHCARE THAILAND
9. Menicon In ninth position is Japan’s largest contact lens manufacturer, Menicon. founded in 1951 and now operating in over 80 countries. In 2019, the company’s total consolidated sales were JP¥84.5 billion up by 4.4%.
8. Konica Minolta Japanese multinational, Konica Minolta, is a technology company headquartered in Marunouchi, Tokyo. Konica Minolta’s Healthcare business sales increased by 3.4% in fiscal 2019. At the start of 2020, the FDA approved the company’s new dynamic X-ray system that enables the visualisation of lung functions, this is expected to boost the company’s earnings in the next fiscal year.
7. Omron Established in 1933, Omron’s primary business is the manufacturing and sale of automation components, equipment and systems, but it is generally known for medical equipment such as digital thermometers, blood pressure monitors and nebulizers and holds an impressive 50% global market share of home blood pressure monitors. In fiscal 2019, sales rose by 2.9% with the demand for blood pressure monitors in China, Europe and Asia remaining high. Meanwhile, demand in Japan was sluggish due to the increase in consumption tax and other factors, while in North America, demand declined too.
6. Fukuda Established in 1939 in Tokyo, Fukuda Denshi has today become one of the largest suppliers of medical equipment solutions in the world. Sales rose by 2.8% in fiscal 2019 with pacemakers and home medical equipment rentals performing well. To improve its positioning going forward, the company has formed a partnership with OMRON Healthcare to help strengthen its home-based field and overseas business.
5. Nihon Kohden At number five is Nihon Kohden, a leading manufacturer, developer, and distributor of medical electronic equipment, including biometric equipment, biometric information monitors, and AEDs. Sales increased by 3.5% as the overall demand for medical equipment remained steady. However, the COVID-19 outbreak adversely affected national healthcare systems, so Nihon Kohden implemented its three-year mid-term business plan, Transform 2020 with the aim of achieving the transformation to a highly profitable structure through creating high customer value and improving productivity.
4. Sysmex With its mission to “shape the advancement of healthcare”, Sysmex has been providing customers around the world with the solutions that enable in vitro testing of blood and urine samples since 1968. Sales for the life science company rose by 2.9% in 2019.
3. Nipro With over 29,000 employees worldwide, Nipro serves the medical device, pharmaceutical, and pharma packaging industries. Nipro’s Medical Device business develops, manufactures, and sells medical equipment for injectioninfusion and dialysis treatment, and products related to diabetes and cell cultures, as well as artificial organrelated products. In 2019, net sales increased by 3.8% from fiscal 2019 due to favourable medical and pharmaceutical sales.
2. Terumo With nearly a century in business, Terumo is in second place. Based in Tokyo and operating globally, Terumo employs more than 25,000 worldwide to provide innovative medical solutions in more than 160 countries. The company started as a Japanese thermometer manufacturer and today it is a strong in cardiovascular areas such as catheters and stents. In fiscal 2019, Terumo posted record highs for revenue and adjusted operating profit due to the relatively strong performance and the fact that the impacts of the global COVID-19 pandemic felt during the fourth quarter were minimal.
1. Olympus Beating Terumo to the top spot is Olympus. With the top share (over 70%) in gastrointestinal endoscopy, the company’s revenues reached ¥641.8 bn in 2019. Growth was due to increased sales in for its Endoscopic Solutions Business, Therapeutic Solutions Business and Scientific Solutions Business. In 2019, announced its business transformation plan “Transform Olympus” in January 2019 to develop itself as a truly global med tech company. Going forward, Olympus is working to achieve sustainable growth based on this management strategy. For More Information : https://www.proclinical.com/blogs/2020-11/who-arethe-top-medical-device-manufacturers-in-japan-2020
DIGITAL ISSUE NO.03 : MAY 2021
21
MEDICAL & Device NEWS By Pharmaceutics International, Inc
Complex Drug Development and Manufacturing-Steroids, Peptides, and Hormones
There are pharmaceutical therapies that are growing in their application and importance in patient care, and they occupy a scientific space between small molecules and biologics. They include steroids, natural and synthetic peptides, and hormones. They are complex, often pose solubility and stability challenges, and combine microbiological and chemical processes. They are also highly potent per dose and expensive–$3000-$4000 per gram. When developing and manufacturing these complex drugs, the risks are significant in terms of product quality, cost, safety, and mistakes can place delivering results to patients in jeopardy. However, risks can be greatly mitigated by the following: preventing cross contamination, employing single-use technology, and using non-destructive testing procedures. Cross Contamination Prevention Plan According to both FDA and EMA, cross-contamination is defined as the adulteration of a starting material, intermediate or finished product with another starting material or product. When not managed properly, cross-contamination poses significant risk to the quality and integrity of a drug product. Whether manufacturing your own product or using a contract development and manufacturing
22
ASIA PHARMED & HEALTHCARE THAILAND
organization (CDMO), cross contamination must be prevented and should be a special focus when working with complex drugs like the ones described above. The Initial Safety Assessment (ASI) of a drug under development contains critical information for preventing cross contamination. A toxicology report is derived from the ASIs and identifies Allowable Daily Exposure (ADE) and defines Acceptable Residue Limits (ARLs). This data informs the Cross-Contamination Risk Assessment which enables the manufacturer to develop the cross-contamination prevention plan. All of this critical data and the processes developed for preventing cross-contamination must be calculated, documented, and measured throughout the manufacturing process. When working with complex formulations in which crosscontamination poses a significant risk to quality, developing the prevention plan is a leadership function and operational leaders must be intimately knowledgeable of the critical details.
Single-Use Technology One way to reduce the time-consuming process of extensively cleaning manufacturing suites is to employ singleuse equipment. As disposable technology has gained in popularity, it has also been improved and can handle the complex formulations containing proteins, steroids,and hormones. Easy to handle disposable bags as small as 1 liter is ideal for the expensive, often highly potent batches noted above. Single-use bags are specially designed to mix, hold, and store batches before and after filtration. Additionally, the material used to manufacture the bags poses no risk related to extractables and leachables. Non-Destructive Testing Every fill-finish operation will incorporate testing to ensure precise dosage amounts and critical quality attributes (CQA), and this is especially important when handling small amounts of highly potent medicines. Over-filling wastes expensive drug product and under-filling impacts quality and patient results. Randomly sampling finished product is less precise and wastes product. Non-destructive testing can save time and money, can ensure quality with precision, and can be performed on an entire batch. A variety of non-destructive means of testing finished product are available to the pharmaceutical in dustry and the best inspection solution should be driven by the product’s critical quality attributes (CQA). Testing can be as straight-forward as a final check-weighing of finished product to complex visual automated inspection systems to detect particulates in the product, check r esidual seal force (RSF), or the integrity of a prefilled syringe.
Summary Developing and manufacturing complex formulations that fall somewhere between small molecule and biologics can be full of challenges: risks that can jeopardize quality, processes that waste costly drug product, and safety concerns for staff and patients. Preventing cross-contamination, employing single-use technology, and conducting nondestructive testing of the finished product will produce higher quality medicines and deliver better results to patients. For More Information : https://www.pharm-int. com/2020/12/28/complex-drug-development-and-manufacturing-steroids-peptides-and-hormones/
DIGITAL ISSUE NO.03 : MAY 2021
23
Medical Technology Association of Japan
The environment surrounding the medical device industry has been Takayoshi Mimura Chairman Medical Technology Association of Japan
changing drastically.
The first thing we need to highlight is that many new technologies have been applied to the medical field in recent years. Technologies, including AI and IoT, will bring new ffects and values beyond the conventional concept of medical devices. New opportunities to develop medical devices also lie in fields such as cell therapy and regenerative medicine. In addition, in the pharmaceutical field, medical device technologies have been drawing much attention to the improvement of treatment adherence, on top of biotechnologies and genomic drug discovery technologies. In this way, new business opportunities for medical devices are expanding beyond the conventional boundaries. We are dedicated to contributing to global healthcare through innovation by incorporating new technologies from different fields and industries, not just staying in the existing industrial framework. Another movement we must address is globalization. Japan’s GDP at the start of the Heisei era (1989) was equivalent to 15% of the world’s GDP, and has now fallen to 6%. Japan is also confronted with many issues such as declining birthrate and aging population. Promoting globalization is inevitable for us, as Japan faces depopulation. In order to promote further globalization, we will continue to corporate with international administrative agencies and related authorities to align our regulation to other countries.
24
ASIA PHARMED & HEALTHCARE THAILAND
The medical device industry today gains substantial expectation from society and our responsibility is heavier than ever before. We strive for the improvement of quality and efficiency of medical treatment globally through the development of superior medical devices. Furthermore, we declare to fulfill our social responsibility for stable supply by reinforcing our capabilities including recovery assistance of natural disaster that frequently occurs. I sincerely appreciate the continued understanding and generous cooperation from all parties.
Composition of Domestic Shipment for MTJAPAN products
For More Information : https://www.mtjapan.or.jp/jp/mtj/en/outline/
MEDICAL TECHNOLOGY PHARMACEUTICAL
6 ISSUES, FULLY DIGITAL ENGLISH CONTENT www.ipriasia.com
If you have an interesting Technical Article or News Update , please send it to us. we will publish it in our Digital Publications. Email to : editors@ipriasia.com
Our magazine and digital publications are read by more than 20,000 readers across the globe. DIGITAL ISSUE For Advertising Digital Contact : lawant@ipriasia.com or sales@ipriasia.com Tel :NO.03 +66: MAY (0)2021 2 392252011
Japan news on covid-19
More than 20
new cases
of Indian COVID-19 variant found
in Japan
The government said it had detected more than 20 cases of the Indian variant of COVID-19 in Japan as of Monday — a rise in the number of cases of a potentially worrisome new strain that some fear could prove more resistant to vaccinations. | REUTERS
26
ASIA PHARMED & HEALTHCARE THAILAND
The government on Monday said it has so far detected more than 20 cases of the Indian variant of COVID-19 in Japan — a rise in the number of cases of the potentially worrisome new strain that some fear could prove more resistant to existing vaccines. “According to the National Institute of Infectious Diseases, a total of 21 cases were confirmed in the country, of which 20 were found in airport quarantine and one was confirmed among domestic cases,” Chief Cabinet Secretary Katsunobu Kato, the government’s top spokesman, told a news conference Monday. The government acknowledged for the first time last week that it had detected five cases of the “double mutant” variant, which has the features of two different viral mutations. India has also detected a “triple mutant” variant, and Kato said that the health ministry was looking into the situation. The double variant, officially known as B.1.617, was first detected in India in October. India has become the global COVID-19 hot spot in recent weeks, setting world records for daily case numbers.
strain has unnerved many observers, who fear it could impact the effectiveness of vaccines. But Kato said there had been no definitive conclusion regarding the efficacy of vaccines against the double variant. “The health ministry is working with other countries, the World Health Organization and experts to collect, evaluate and analyze information pertaining to variants, not just the one found in India,” Kato said, vowing to bolster quarantine arrangements as part of border control measures and screening for variants inside the country. One senior administration official did acknowledge that stifling the variant completely within Japan would be “difficult” if it began to spread more widely. As of Monday afternoon, there had been no reports of any ariants involving three or more mutations being detected in Japan. For More Information ; https://www.japantimes.co.jp/news/2021/04/26/national/ indian-variant-coronavirus-japan/
Although it’s unclear whether the new variant has fueled the explosive spread of cases, the existence of the new
DIGITAL ISSUE NO.03 : MAY 2021
27
world news on covid-19
Morals
and unevenly, across richer countries, but flaring up in several developing and emerging economies, most notably India, but also to varying degrees in countries such as Bangladesh, Pakistan, Turkey, the Philippines, Ethiopia, and Kenya.
COVID-19
There are many reasons for this divide, but uneven access to health care - particularly the glaring inequity in access to COVID-19 vaccines - is impossible to ignore. On Jan. 18, the director-general of the World Health Organization, Tedros Ghebreyesus, noted that more than 39 million doses of COVID-19 vaccine had been administered in at least 49 higher-income countries. By contrast, he said, “Just 25 doses have been given in one lowest-income country. Not 25 million; not 25 thousand; just 25.”
and the
vaccine
market THACA, NEW YORK – As the second wave of the COVID-19 pandemic outstrips the severity of the first, a clear global bifurcation is emerging. The pandemic is abating, gradually
28
ASIA PHARMED & HEALTHCARE THAILAND
More than 1 billion vaccine doses have now been administered worldwide, but vast disparities remain. Seychelles tops the list, having fully vaccinated 59% of its citizens, while Israel (56%), Chile (34%), and the United States (30%) also rank high. Brazil, however, is 43rd globally, with just 5.9% of its population fully vaccinated, while India and Bangladesh are much lower, at 1.8% and 1.7%, respectively. And in some countries, mainly in SubSaharan Africa, virtually no one has been vaccinated.
Given that a COVID-19 vaccine is an essential good like food and shelter, we should be ashamed of such grave inequities. Making the problem worse, many rich countries are stock piling vaccines beyond what they need, as a precautionary buffer. Until a few months ago, activists for access to medicines and open science were hopeful that the enormity of the pandemic would lead to a rejection of proprietary science and patent-based market monopolies. In May 2020, for example, the WHO launched the global COVID-19 Technology Access Pool (C-TAP) with the aim of encouraging the widespread voluntary sharing of pandemic-related intellectual property. Similarly, the COVID-19 Vaccine Global Access (COVAX) facility, also established last year, was supposed to provide subsidized vaccines to poor countries, with financial support from the rich world. But even by then, as Alexander Zaitchik - echoing a common sentiment - recently wrote in The New Republic, “the optimism and sense of possibility that defined the early days were long gone.” If we reflect on the world’s failure to ensure equitable access to COVID-19 vaccines, we will at least be less likely to leave poor countries in the lurch in the future. The failure is both intellectual and moral. With the best of intentions, many activists’ plans and proposals paid little attention to individual incentives. But while it is right to campaign for corporations to behave morally, it is folly to assume they are moral. We can conceive of a future where people invest in knowledge creation and then contribute their findings to an openaccess pool, instead of trying to make money. But we clearly are not there yet. For now, we must let private players acquire rights over the intellectual property they create to ensure that they invest in costly research. At the same time, there is scope for cutting the profits of pharmaceutical firms considerably - by compelling them to sell products more cheaply and enable generic producers to sell in certain regions - without killing the pharmaceutical Industry’s incentives to spend on research.
To do this properly, we need to understand the structure of markets for knowledge-based products like new vaccines. Currently, we do not: The “market” is a mishmash of competition and side deals. According to a recent paper from the Institute for New Economic Thinking, governments and pharmaceutical companies
last year concluded 44 bilateral COVID-19 vaccine deals, many of which have undisclosed details and poorly understood escape clauses. Poor countries were, by and large, left out. We sorely need a theoretical framework to understand this market. Currently, it resembles what oligopoly must have looked like before Augustin Cournot captured its essentials in 1838. Cournot’s breakthrough later enabled the development of the first antitrust laws, like the U.S. Sherman Antitrust Act of 1890, which allowed firms to set prices but prohibited secret multilateral deals to prop up prices. These laws gradually became sharper. Today, we are making vaccine-market rules while trapped in a fog of uncertainty. From the little we know, it is clear that intellectual-property rights must continue to play a role, at least for now. On the other hand, pharmaceutical firms are arguably making vastly larger profits than needed to sustain their incentive to innovate (especially given how much of their IP has resulted from publicly funded research). In large pandemics such as the current one, we should compensate drug companies with lump-sum payments to cover costs, revoke some of their patents, and allow generic firms to mass-produce essential vaccines. In the long run, we can go further, by emphasizing that a society’s success does not depend on profit alone. The popular slogan, “None of us will be safe until everyone is safe,” amounts to urging the rich to be more selfish, because helping others is in their self-interest. But the pandemic is a clarion call to start thinking beyond the narrow confines of economic rationality and identify others’ interests as part of our own. For More Information : https://www.japantimes.co.jp/opinion/2021/05/03/commentary/world-commentary/covid-19-vaccinations-whopoor-rich-countries/
DIGITAL ISSUE NO.03 : MAY 2021
29
INDUSTRY ASSOCIATION
by BOI & THE EUROPEAN HOUSE – AMBROSETTI
OPPORTUNITIES IN THAILAND FOR THE ITALIAN MEDICAL AND HEALTHCARE VALUE CHAIN
Thursday, April 22, 2021 (9.30 am – 11.00 am CET time) In recent years, Thailand has been strengthening its position as the “Medical Hub of Asia”, thanks to a strong healthcare infrastructure and an international reputation for its highly skilled medical professionals and international standard medical services. Thailand’s demand for healthcare services and products is rising and will increasingly do so in the years to come, due to the rise of Thailand’s aging population. Thailand is also a leading medical tourism hub, with the number of foreign patients at Thai hospitals increasing at a very rapid rate. Moreover, Thailand’s medical devices sector is the 8th largest in the Asia-Pacific region, with an estimated 600 local medical device manufacturers. Suppliers can also be found in Thailand for rubber, metal, plastics, and electronics parts used along the medical and healthcare value chain. As the Thai government considers the healthcare industry to be a priority sector for investment and further development, the Board of Investment offers a wide range of incentives for investment projects, making Thailand the ideal investment destination for medical and healthcare service, product, and technology providers.
30
ASIA PHARMED & HEALTHCARE THAILAND
This webinar represents an opportunity to discuss the investment opportunities in Thailand’s medical and healthcare sector, thanks to the intervention of high-level institutional representatives from Thailand, starting from the Board of Investment, and the presentation of a concrete case study of an Italian firm which successfully invested in Thailand. Among the confirmed speakers: Lorenzo Galanti (Ambassador of Italy to Thailand), Alberto La Lumia (Director Internazionale, Vittoria Group), Chirdchu Raktabutr (Ambassador of Thailand to Italy), Kritsana Saeheng (Senior Investment Promotion Officer, Thailand Board of Investment), Lorenzo Tavazzi (Partner and Responsible for International Development, The European House Ambrosetti). The following personalities will also participate as speakers: an executive from the Thailand Food and Drug Administration and an executive from the Medical and Health Device Manufacturers Industry Club of The Federation of Thai Industries. For More Information : https://www.ambrosetti.eu/en/
INDUSTRY ASSOCIATION bY WHO THAILAND
Hope for humanity
the Mor Prom application, created to support the national vaccine programme, eases the process of storing personal data in a systematic way, minimizes time spent dealing with paperwork and speeds up the administration process as well as the vaccination process altogether. “I really hope everyone takes the time to understand this application, purely for their own benefit,” says Dr. Puritat Sangtongpanichakul. Dr. Puritat Sangtongpanichakul, Deputy Director, Ratchaphiphat Hospital
In an age where almost everything is being digitised, “Before, we were recording a patient’s personal data manually, but with the introduction of the Mor Prom application, everything is made easier. You automatically have everything stored in this app - the date you received the vaccine, the name of the vaccine, its serial number, batch number, whether you’re taking the first or second dose. The app also sends out a warning message requesting each vaccinee to report any adverse effects from inoculation. It’s all very convenient.”
“Before, we were recording a patient’s personal data manually, but with the introduction of the Mor Prom application, everything is made easier. You automatically have everything stored in this app - the date you received the vaccine, the name of the vaccine, its serial number, batch number, whether you’re taking the first or second dose. The app also sends out a warning message requesting each vaccine to report any adverse effects from inoculation. It’s all very convenient.” For More Information : https://www.who.int/thailand/news/feature-stories/detail/ hope-for-humanity
patients and healthcare workers are maximizing the use of technology to their own advantage. The introduction of
DIGITAL ISSUE NO.03 : MAY 2021
31
Event calendar China International Medical Equipment Fair 13 - 16 May 2021 NECC (Shanghai, China) https://www.cmef.com.cn/en Reed Sinopharm
Pharma B2B Expo 22 - 23 May 2021
SBW·CIHIE Medical Health Industry Expo 17 - 19 May 2021 China International Exhibition Center
http://en.yaok.cn Shibowei International Exhibition Group
Australian Pharmacy Professional Conference and Trade Exhibition
20 -23 May 2021
17 - 19 May 2021 China International Exhibition Center
http://en.jianbohui.com/ Shibowei International Exhibition Co. Ltd.
International Medical Instruments and Equipment Exhibition
24 - 26 May 2021
http://pharmab2bexpo.com/expo.php
Gold Coast Convention and Exhibition Centre
China National Convention Center, Beijing, China
Welldone Media Pvt.Ltd
www.appconference.com
China World International Exhibition Co. Ltd.
Hitex Exhibition Center, Hyderabad, India
The Pharmacy Guild of Australia
KOREA PHARM & BIO 25 - 28 May 2021 Kintex, Goyang-si, South Korea www.koreapharm.org/eng/ Kyungyon Exhibition Corp.
Wellness Life Japan 9-11 June 2021 Tokyo Big Sight, Koto, Japa www.wfjapan.com/tokyo/ TSO International Inc. 32
China International Health Industry Expo Beijing
ASIA PHARMED & HEALTHCARE THAILAND
EgyMedica 27 - 29 May 2021 Cairo International Convention Centre
https://www.egymedica.com GREENLAND
InterCare Asia 2021 8-10 July 2021 BITEC https://intercare-asia.com/ N.C.C. EXHIBITION ORGANIZER CO., LTD.
www.chinamed.net.cn
International Pharmaceutical Conference and Expo
27 - 28 May 2021 Park Inn by Radisson London Heathrow, London, UK
www.ipharmaconference.com IPHARMA
Bangladesh Medical & Healthcare Virtual Expo 12 – 15 July 2021 VIRTUAL PLATFORM = Bee2Bee.asia https://www.worldexindia.com/medhealthexpos/bdmhve/ Worldex India Exhibition & Promotion Pvt. Ltd.
600 THB
US$ 22
6 Issues/years
Please fill in this form and fax or post to circulation Department, IPRI Co.,Ltd. 58/2 Soi Promsri Sukhumvit 49/9 , Klongton Nua, Wattana, Bangkok 10110 Thailand. Tel. : +66 (02) 392 2011 Fax : +66 (02) 392 2012 Website : www.asiapmh.com DIGITAL ISSUE NO.03 : MAY 2021
33
Limited Booths Available Book Your Space Today
Zahir Merchant (Sr. Manager) +(91)-9820028359 zahir@worldexindia.com
Medical Device Distributors and Agents
Participation Benets Designer Virtual Booth
Pre-fixed B2B Meetings with Buyers
Live Chat, Video Calls with Visitors
30 Products Showcase
Upload Brochures & Videos
Share Business Cards
Request for Quote (RFQ)
Your Visitors Database & Report
34
ASIA PHARMED & HEALTHCARE THAILAND
